


## Our User Flow

44



# Phyla

<https://www.phyla.ai/>

#CROHNS #COLITIS #IBS

### VALUE FOR CLIENT

Phyla's AI-enabled platform monitors digestive diseases using affordable stool microbiome testing and user-reported health information.

### BUSINESS CASE

Gut disease affects 37 million North-Americans and represents \$77B in annual healthcare spending. There is no cure for IBD and prognostics are poor.

### VALUE FOR USER

Phyla's algorithm detects negative patterns detrimental to intestinal health and displays these to the user or caregiver for early mitigation.

### INSIGHTS

IBD/IBS patients must endure: weak immunity, poor quality of life, repeat colonoscopies, vague diagnostics and frequent trips to the hospital.

## Phyla's new approach to gut health monitoring: longitudinal data driven insights using both biological and self-reported sources

Using the stool microbiome, our AI data processing pipeline can non-invasively detect IBD. This is then combined with user self-reported data from our digital health app (symptoms, medication compliance, diet, mood), we create a comprehensive data set comprising a longitudinal and holistic view of lifestyle, microbiome and patient outcomes. Data visualization allows us to show patients the links between their disease state, lifestyle, medication compliance and more. Using regular testing, personalized recommendations and educational materials, our platform will empower patients to take control of their disease by improving their disease understanding and quality of life.

### DATE OF CREATION

April 1st 2020

### GEOGRAPHIC COVERAGE

Canada, USA

### HQ LOCALIZATION

Montreal, Québec, Canada

### FOUNDERS

Lucca Cuccia, CEO  
Ryszard Kubinski, CSO  
Michael Golfi, CTO  
Paul Godin, COO

### FUNDINGS

\$400k total

### INVESTORS

Techstars Montreal AI 2019,  
MEDTEQ, La MAIN, Centech